~~WHAT IS~~ CLAIM~~ED I~~S:

1. A delivery vehicle for inhibiting expression of a gene expressed in skeletal muscle cells comprising:

(a) an RNAi agent comprising:

(i) an antisense strand comprising 17-49 nucleotides wherein at least 15 nucleotides are complementary to the mRNA sequence of a gene that is expressed in skeletal muscle cells

(ii) a sense strand that is 16-49 nucleotides in length that is at least partially complementary to the antisense strand;

(b) a targeting ligand with affinity for a receptor present on the surface of a skeletal muscle cell, wherein the targeting ligand is a polypeptide; and

(c) a PK/PD modulator;

wherein the RNAi agent is covalently linked to the targeting ligand and to the PK/PD modulator.

~~2. The delivery vehicle of claim 1, wherein the targeting ligand has affinity for an integrin receptor.~~


~~3. The delivery vehicle of any one of claims 1-2, wherein the targeting ligand has affinity for the αvβ6 integrin receptor.~~


~~4.~~2. The delivery vehicle of ~~any one of~~ claim~~s~~ 1~~-3~~, wherein the polypeptide of the targeting ligand is a polypeptide of Formula (**P**):

$$Xaa^1G'DLXaa^2Xaa^3L\text{-}Xaa^4Xaa^5L—\{$$

(**P**)

or a pharmaceutically acceptable salt thereof, wherein

Xaa^1 is L-arginine optionally having an N-terminal cap, ,

or , wherein each $\{^*$ indicates a point of connection to G';

G' is L-glycine or N-methyl-L-glycine;

D is L-aspartic acid (L-aspartate);

L is L-leucine;

Xaa^2 is an L-α amino acid, an L-β amino acid, or an α,α-disubstituted amino acid;

Xaa^3 is an L-α amino acid, an L-β amino acid, or an α,α-disubstituted amino acid;

Xaa^4 is an L-α amino acid, an L-β amino acid, or an α,α-disubstituted amino acid;

Xaa^5 is an L-α amino acid, an L-β amino acid, or an α,α-disubstituted amino acid; and

$\lesssim$ indicates a point of connection to the RNAi agent.

~~5. The delivery vehicle of claim 4, wherein Xaa^2 is L-alanine or L-glycine.~~

~~6. The delivery vehicle of claim 4, wherein Xaa^2 is L-alanine.~~

~~7. The delivery vehicle of any one of claims 4-6, wherein Xaa^3 is a non-standard amino acid.~~

~~8. The delivery vehicle of any one of claims 4-7, wherein Xaa^3 is L-alanine, L-glycine, L-valine, L-leucine, L-isoleucine, or L-α-amino-butyric acid.~~

~~9. The delivery vehicle of any one of claims 4-7, wherein Xaa^3 is L-α-amino-butyric acid.~~

~~10. The delivery vehicle of any one of claims 4-7, wherein Xaa^4 is L-arginine, L-citrulline, or L-glutamine.~~


~~11. The delivery vehicle of any one of claims 4-9, wherein Xaa^4 is L-citrulline.~~

~~12. The delivery vehicle of any one of claims 4-11, wherein Xaa^5 is L-glycine, L-alanine, L-valine, L-leucine, L-isoleucine, or α-amino-isobutyric acid.~~

~~13. The delivery vehicle of any one of claims 4-11, wherein Xaa^5 is α-amino-isobutyric acid.~~


~~14. The delivery vehicle of any one of claims 4-13, wherein Xaa^+ is N-acetyl-L-arginine.~~

~~15. The delivery vehicle of any one of claims 4-13, wherein Xaa^+ is~~




~~, wherein ~~  ~~ indicates a point of connection to G'.~~

~~16. The delivery vehicle of any one of claims 4-13, wherein Xaa^+ is~~




~~, wherein ~~  ~~ indicates a point of connection to G'.~~

~~17.~~3. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:




or a pharmaceutically acceptable salt thereof, wherein indicates a point of connection to the remainder of the delivery vehicle.

~~18.~~4. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:




or a pharmaceutically acceptable salt thereof, wherein ≀ indicates a point of connection to the remainder of the delivery vehicle.

~~19.~~5. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:




or a pharmaceutically acceptable salt thereof, wherein ≀ indicates a point of connection to the remainder of the delivery vehicle.

~~20.~~6. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:




or a pharmaceutically acceptable salt thereof, wherein ≀ indicates a point of connection to the remainder of the delivery vehicle.

~~21.~~7. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:



or a pharmaceutically acceptable salt thereof, wherein ≀ indicates a point of connection to the remainder of the delivery vehicle.

~~22.~~8. The delivery vehicle of claim 1, wherein the targeting ligand has the formula:




or a pharmaceutically acceptable salt thereof, wherein ≀ indicates a point of connection to the remainder of the delivery vehicle.

~~23. The delivery vehicle of any one of claims 1-22, wherein the PK/PD modulator comprises at least one polyethylene glycol (PEG) unit.~~


~~24. The delivery vehicle of any of claims 1-22, wherein the PK/PD modulator comprises at least ten PEG units.~~

~~25.~~9. The delivery vehicle of any one of claims 1-8~~24~~, wherein the PK/PD modulator is:




PEG40K (2x2-arm),

wherein n and m are each independently integers, and the molecular weight of the sum of all PEG units is about 40 kilodaltons




PEG40K (4-arm),

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 40 kilodaltons




PEG40K (2-arm),

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 40 kilodaltons




PEG40K,

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 40 kilodaltons




PEG10K,

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 10 kilodaltons




PEG5K,

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons




DSPE-PEG5K-NHS

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons




DSPE-PEG5K-MAL

Wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons




DSPE-PEG5K-N3


wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons




PEG47+C22




PEG47+CLS (cholesterol)




PEG23+C22




Bis(PEG23+C14)




Bis(PEG23+C22)




Bis(PEG47+C22)




PEG48+C22




PEG71+C22




PEG95+C22




PEG71+CLS




PEG95+CLS




Bis(PEG23+C18)




Tris(PEG23+C22)



Tris(PEG23+CLS)




Bis(PEG23+CLS)




PEG5K+C22

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons




C18




(NHS)-PEG1K+C18

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 1 kilodalton




(NHS)-PEG2K+C18

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 2 kilodaltons




(NHS)-PEG5K+C18

wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons



(MAL)-PEG5K+C18


wherein n is an integer, and the molecular weight of the sum of all PEG units is about 5 kilodaltons



PEG48+C18

or a pharmaceutically acceptable salt of any of these PK/PD modulators, wherein ≀ indicates a point of connection to the RNAi agent.

~~26.~~10. The delivery vehicle of any one of claims 1-9~~22~~, wherein the PK/PD modulator is a PK/PD modulator of Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof, wherein

L_A is a bond or a bivalent moiety connecting Z to the RNAi agent;

Z is CH, phenyl, or N;

L_1 and L_2 are each independently linkers comprising at least about 5 PEG units;

X and Y are each independently lipids comprising from about 10 to about 50 carbon atoms; and

≀ indicates a point of connection to the RNAi agent.

~~27. The delivery vehicle of claim 26, wherein L_1 and L_2 each independently comprise about 15 to about 100 PEG units.~~





~~28. The delivery vehicle of claim 26 or 27, wherein L_1 and L_2 each independently comprise about 20 to about 60 PEG units.~~









~~29. The delivery vehicle of any one of claims 26-28, wherein L_1 and L_2 each independently comprise about 20 to about 30 PEG units.~~

~~30. The delivery vehicle of any one of claims 26-28, wherein L_1 and L_2 each independently comprise about 40 to about 60 PEG units.~~

~~31. The delivery vehicle of claim 26, wherein one of L_1 and L_2 comprises about 20 to about 30 PEG units and the other comprises about 40 to about 60 PEG units.~~

~~32. The delivery vehicle of claim 26, wherein each of L_1 and L_2 is independently selected from the group consisting of:~~

~~Name~~	~~Structure~~
~~Linker 1~~	
~~Linker 2~~	
~~Linker 3~~	
~~Linker 4~~	

~~Name~~	~~Structure~~
~~Linker 5~~	
~~Linker 6~~	
~~Linker 7~~	
~~Linker 8~~	
~~Linker 9~~	
~~Linker 10~~	
~~Linker 11~~	
~~Linker 12~~	

~~wherein,~~

~~each *p* is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30;~~

~~each *q* is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30;~~

~~each *r* is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and~~

~~each ≈ indicates a point of connection to X, Y, or Z; provided that~~

~~(i) in Linker 1, 6, and 11, $p + q + r \geq 5$;~~

~~(ii) in Linker 2, 3, 7, 8, 9, and 10, $p + q \geq 5$; and~~

~~(iii) in Linker 4 and 5, $p \geq 5$.~~


~~33. The delivery vehicle of claim 32, wherein~~

~~each *p* is independently 20, 21, 22, 23, 24, or 25;~~

~~each *q* is independently 20, 21, 22, 23, 24, or 25; and~~

~~each *r* is independently 2, 3, 4, 5, or 6.~~


~~34.~~11. The delivery vehicle of claim 10~~26~~, wherein the PK/PD modulator of Formula (**I**) is a PK/PD modulator of Formula (**Ia**):



(**Ia**)

or a pharmaceutically acceptable salt thereof.


~~35.~~12. The delivery vehicle of claim 10~~26~~, wherein the PK/PD modulator of Formula (**I**) is a PK/PD modulator of Formula (**Ib**):



(**Ib**)

or a pharmaceutically acceptable salt thereof.

~~36.~~13. The delivery vehicle of claim 10~~26~~, wherein the PK/PD modulator of Formula (**I**) is a PK/PD modulator of Formula (**Ic**):



(**Ic**)

or a pharmaceutically acceptable salt thereof.

~~37. The delivery vehicle of any one of claims 26-36, wherein at least one of X and Y is an unsaturated lipid.~~

~~38. The delivery vehicle of any one of claims 26-37, wherein at least one of X and Y is a saturated lipid.~~











~~39. The delivery vehicle of any one of claims 26-38, wherein at least one of X and Y is a branched lipid.~~











~~40. The delivery vehicle of any one of claims 26-39, wherein at least one of X and Y is a straight chain lipid.~~




~~41. The delivery vehicle of any one of claims 26-40, wherein at least one of X and Y is a lipid comprising from about 10 to about 25 carbon atoms.~~

~~42. The delivery vehicle of any one of claims 26-41, wherein at least one of X and Y is cholesteryl.~~

~~43.~~14. The delivery vehicle of any one of claims 10-13~~26-36~~, wherein at least one of X and Y is selected from the group consisting of:





Name	Structure
Lipid 1	
Lipid 2	
Lipid 3	
Lipid 4	
Lipid 5	
Lipid 6	
Lipid 7	
Lipid 8	
Lipid 9	
Lipid 10	












Name	Structure
Lipid 11	
Lipid 12	
Lipid 14	
Lipid 15	
Lipid 16	
Lipid 17	
Lipid 18	
Lipid 19	
Lipid 20	
Lipid 21	









Name	Structure
Lipid 22	
Lipid 23	
Lipid 24	

wherein  indicates a point of connection to L_1 or L_2.

~~44. The delivery vehicle of any one of claims 26-36, wherein both X and Y are each independently selected from the group consisting of:~~

~~Name~~	~~Structure~~
~~**Lipid 1**~~	
~~**Lipid 2**~~	
~~**Lipid 3**~~	
~~**Lipid 4**~~	









~~Name~~	~~Structure~~
~~Lipid 5~~	
~~Lipid 6~~	
~~Lipid 7~~	
~~Lipid 8~~	
~~Lipid 9~~	
~~Lipid 10~~	
~~Lipid 11~~	
~~Lipid 12~~	
~~Lipid 14~~	
~~Lipid 15~~	
~~Lipid 16~~	







Name	Structure
Lipid 17	
Lipid 18	
Lipid 19	
Lipid 20	
Lipid 21	
Lipid 22	
Lipid 23	
Lipid 24	

wherein  indicates a point of connection to L_1 or L_2.

45. The delivery vehicle of claim 26, wherein L_A is selected from the group consisting of:

Name	Structure

~~Tether 1~~	
~~Tether 2~~	
~~Tether 3~~	
~~Tether 4~~	
~~Tether 5~~	
~~Tether 6~~	
~~Tether 7~~	
~~Tether 8~~	

~~Tether 9~~	
~~Tether 10~~	
~~Tether 11~~	
~~Tether 12~~	
~~Tether 13~~	
~~Tether 14~~	

~~wherein, each of *m*, *n*, *o*, and *a* is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, and each ≈ indicates a point of connection to Z or the RNAi agent.~~

~~46. The delivery vehicle of claim 45 wherein,~~




~~each *m* is independently 1, 2, 3, 4, 5,6, 7, 8, 8, 9, 10, 20, 21, 22, 23, 24, or 25;~~


~~each *n* is independently 2, 3, 4, or 5;~~

~~each *a* is independently 2, 3, or 4; and~~


~~each *o* is independently 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13.~~

~~47.~~15. The delivery vehicle of claims 1-~~8~~22, wherein the PK/PD modulator is selected from the group consisting of:


LP 1b

LP 28b

LP 29b

LP 38b




LP 39b




LP 41b




LP 42b




LP 43b




LP 44b




LP 45b




LP 47b




LP 48b




LP 49b




LP 53b




LP 54b




LP 55b




LP 56b




LP 57b




LP 58b




LP 59b




LP 60b




LP 61b




LP 62b




LP 87b




LP 89b




LP 90b




LP 92b




LP 93b




LP 94b




LP 95b




LP 101b




LP 102b




LP 103b




LP 104b




LP 106b




LP 107b




LP 108b




LP 109b




LP 110b




LP 111b




LP 124b




LP 130b




LP 143b




LP 210b




LP 217b




LP 220b




LP 221b




LP 223b




LP 224b




LP 225b




LP 226b




LP 238b




LP 240b




LP 246b






LP 247b



LP 339b



LP 340b

LP 357b

LP 358b


or a pharmaceutically acceptable salt of any of these PK/PD modulators, wherein each ≈ indicates a point of connection to the RNAi agent.

~~48.~~16. The delivery vehicle of any one of claims 1-15~~47~~, wherein the RNAi agent inhibits expression of the mRNA of a human gene in a skeletal muscle cell.

~~49.~~17. The delivery vehicle of any one of claims 2-16~~4-48~~, wherein the pharmaceutically acceptable salt is a sodium salt.

~~50. The delivery vehicle of any one of claims 4-48, wherein the pharmaceutically acceptable salt is a potassium salt.~~

~~51.~~18. A composition comprising the delivery vehicle of any one of claims 1-17~~50~~.

~~52.~~19. A pharmaceutical composition comprising the composition of claim 18~~51~~ and a pharmaceutical excipient.

~~53.~~20. The pharmaceutical composition of claim 19~~52~~, wherein the pharmaceutical excipient is selected form water for injection and saline solution.

~~54.~~21. The pharmaceutical composition of claim 20~~53~~, wherein the pharmaceutical excipient is saline solution.

~~55.~~22. A ~~method of~~composition comprising the delivery vehicle of any one of claims 1-17 for use in treating a disease or disorder of a skeletal muscle cell~~ comprising administering to a subject in need thereof a composition of claim 51 or a pharmaceutical composition of any one of claims 52-54~~.

~~56.~~23. The ~~method~~composition of claim 22~~55~~, wherein the disease or disorder is muscular dystrophy.

~~57.~~24. The ~~method~~composition of claim 23~~56~~, wherein the muscular dystrophy is selected from the group consisting of: Duchenne muscular dystrophy, myotonic muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy.

~~58. Use of the delivery vehicle of any one of claims 1-50, the composition of claim 51, or the pharmaceutical composition of any one of claims 52-54, for the delivery of an RNAi agent to a skeletal muscle cell.~~

~~59. The use according to claim 58, wherein the skeletal muscle cell is within a subject.~~

~~60. The use according to claim 59, wherein the subject is a human subject.~~

~~61. The use according to any one of claims 58-60, wherein the RNAi agent inhibits expression of a target gene in the skeletal muscle cell by at least about 50%.~~

~~62. The use according to claim 61, wherein the target gene is myostatin (Mstn.).~~

~~63.~~25. Use of the delivery vehicle of any one of claims 1-17~~50~~, the composition of claim 51, or the pharmaceutical composition of any one of claims 52-54, for the preparation of a medicament for the treatment of a disease or disorder.

~~64.~~26. The use of claim 25~~63~~, wherein the disease or disorder is a muscular dystrophy.

~~65.~~27. The use of claim 26~~64~~, wherein the muscular dystrophy is selected from the group consisting of: Duchenne muscular dystrophy, myotonic muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, congenital muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy.

~~66.~~28. A method of making the delivery vehicle of any one of claims 1-17~~50~~, the method comprising:

(i) synthesizing the sense strand;

(ii) synthesizing the antisense strand;

(iii) annealing the sense strand and the antisense strand;

(iv) before or after annealing the sense strand and the antisense strand, conjugating the targeting ligand to the sense strand or the antisense strand; and

(v) before or after annealing the sense strand and the antisense strand, and before or after conjugating the targeting ligand to the sense strand or the antisense strand, conjugating the PK/PD modulator to the sense strand or the antisense strand.